Key Takeaways Omnicell reports Q2 2026 results on July 30, with revenues seen rising 6.6% and EPS expected to grow 6.7%. OMCL may benefit from OmniSphere adoption, customer wins and Titan XT traction across health systems. Omnicell's Product and Services revenue growth is expected to reflect demand and recurring software momentum. Omnicell (OMCL - Free Report) is set to release second-quarter 2026 results on July 30, before market open.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of 55 cents, which surpassed the Zacks Consensus Estimate by 66.67%. Omnicell beat on earnings in three of the trailing four quarters and missed on one occasion, the average surprise being 34.65%.
OMCL’s Q2 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $309.6 million, which suggests 6.6% growth from the year-ago reported figure.
The Zacks Consensus Estimate for earnings is pinned at 48 cents per share, which implies a 6.7% rise from the year-ago recorded actuals.
Estimate Revision Trend Ahead of OMCL’s Q2 EarningsEstimates for second-quarter earnings have remained unchanged at 48 cents per share in the past 30 days.
Here’s a brief overview of the company’s performance leading up to this announcement.
Factors Shaping OMCL’s Q2 PerformanceThe company is expected to have delivered another quarter of solid growth, supported by continued execution of its Connected Devices strategy and expanding recurring revenue streams. Demand is likely to have remained strong across inpatient and outpatient pharmacies as well as broader patient care settings, reflecting continued adoption of Omnicell's medication management solutions.
Second-quarter revenue growth is also expected to have been supported by increasing penetration of OmniSphere, a cloud-native medication management platform, as healthcare providers continue to prioritize enterprise-wide automation, workflow optimization and data-driven medication management.
The second-quarter top line is also likely to have benefited from continued customer wins among large and complex health systems. The recently launched Titan XT next-generation automated dispensing system is expected to have gained further commercial traction, supported by its integration with the OmniSphere platform. The combined offering is likely to have strengthened Omnicell's value proposition by providing enterprise-wide visibility, guided clinical workflows and a modern cloud-based infrastructure designed for large healthcare organizations.
From a segment perspective, Product revenues are expected to have benefited from sustained demand for the Connected Devices portfolio across both North America and international markets, supported by ongoing capital investments from healthcare providers.
The Zacks Consensus Estimate for Product revenues indicates 5.2% year-over-year growth for the second quarter.
Service revenues are likely to have remained on a growth trajectory, supported by higher recurring software and service revenues, including continued momentum in Specialty Pharmacy Services. This growth is expected to have been driven by increasing customer adoption of subscription-based and technology-enabled medication management solutions.
The Zacks Consensus Estimate for Services revenues indicates 5% year-over-year growth for the second quarter.
Omnicell, Inc. Price and EPS SurpriseWhat Our Quantitative Model Predicts for OMCLPer our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates. However, this is not the case here, as you can see below:
Earnings ESP: Omnicell has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank stocks here.
Top MedTech PicksHere are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:
Hinge Health Inc. (HNGE - Free Report) has an Earnings ESP of +4.24% and a Zacks Rank #1 at present. The company is expected to release second-quarter 2026 results soon.
In the trailing four quarters, HINGE delivered an average earnings surprise of 179.54%. The Zacks Consensus Estimate for second-quarter EPS implies a decrease of 11.9% from the year-ago quarter’s figure.
Neurocrine Biosciences (NBIX - Free Report) has an Earnings ESP of +40.60% and a Zacks Rank #1 at present. The company is expected to release second-quarter 2026 results soon.
NBIX’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 9.08%. The Zacks Consensus Estimate for the company’s second-quarter EPS calls for an increase of 112.3% from the year-ago quarter’s figure.
West Pharmaceutical Services (WST - Free Report) has an Earnings ESP of +1.09% and a Zacks Rank #2 at present. The company is slated to release second-quarter 2026 results on July 23.
WST’s earnings beat estimates in each of the trailing four quarters, the average surprise being 19.37%. The Zacks Consensus Estimate for WST’s second-quarter EPS implies a rise of 13% from the year-ago reported figure.
Key Takeaways Omnicell is advancing autonomous pharmacy with new solutions and major health system wins. OMCL expanded its SaaS and Expert Services portfolio through acquisitions and new customer commitments. OMCL's 2026 guidance includes about $12M in tariff-related costs amid competitive pressure. Omnicell (OMCL - Free Report) is well poised to grow in the coming quarters as it continues to steadily advance the autonomous pharmacy industry-defined vision for delivering improved medication management outcomes. The company is expanding its SaaS and Expert Services portfolio via acquisitions and new platform launches. However, macroeconomic headwinds and competitive pressures could weigh on its operating performance.
Over the past year, this Zacks Rank #3 (Hold) stock has had a remarkable run. OMCL shares have risen 51.6% compared to the industry’s 21.2% decline. The S&P 500 composite has grown 23.2% during the same time frame.
The renowned healthcare technology company has a market capitalization of $1.96 billion. OMCL’s earnings yield of 4.7% is comfortably above the industry’s negative 1% yield. In the trailing four quarters, Omnicell surpassed earnings estimates thrice and missed on one occasion, the average surprise being 34.7%.
Let’s delve deeper.Tailwinds for OMCL StockAutonomous Pharmacy Model Holds Potential: The industry-defined vision of Autonomous Pharmacy is a roadmap to improving operational efficiencies and ultimately targeting zero-error medication management. Over the past several years, the company has expanded its business from a single-point solution to a platform of products and services that will help further advance the vision.
OMCL also secured several wins with major health systems and government health care facilities. Its ongoing R&D investments across Points of Care, Central Pharmacy and IV Compounding, Specialty Pharmacy and 340B Program and Ambulatory Care market categories are expected to deliver solutions that drive positive medication management outcomes for customers.
Robust Pipeline for SaaS and Expert Services Portfolio: Omnicell derives an increasing portion of revenues from its subscription-based SaaS and Expert Services offerings, which includes a combination of robotics, smart devices and intelligent software, all optimized by expert services.
In recent years, the company has integrated three key acquisitions — Specialty Pharmacy Services, FDS Amplicare, and MarkeTouch Media. In the first quarter of 2026, several health systems committed to using Omnicell's inventory optimization service, alongside central pharmacy automation and point-of-care dispensing solutions.
Image Source: Zacks Investment Research
What Ails OMCL Stock?Escalating Expenses May Strain Margins: In response to changing tariffs, several foreign countries have imposed reciprocal duties on U.S.-manufactured goods. Changes in export or import regulations and other trade barriers may have an adverse effect on the company’s business. OMCL’s 2026 guidance incorporates an updated estimate of approximately $12 million in tariff-related costs impacting the P&L.
Competitive Landscape: Omnicell faces intense competition in the medication management and supply-chain solutions market. Major direct competitors in the medication packaging solutions market pose threats as they spearhead several expansion programs. This increased competition could result in pricing pressure and a reduced margin, which would have an adverse impact on the company’s performance.
OMCL Stock Estimate TrendThe Zacks Consensus Estimate for OMCL’s 2026 earnings per share (EPS) has jumped $1.97 in the past 30 days.
The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $1.24 billion, suggesting a 4.9% increase from the year-ago reported number.
Key PicksSome better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Integra LifeSciences (IART - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Globus Medical has an earnings yield of 5.5%, well ahead of the industry’s negative 3% yield. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.3%. The company’s shares have rallied 43.8% against the industry’s 4.8% decline over the past year.
GMED carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Integra LifeSciences, carrying a Zacks Rank #2 at present, has an earnings yield of 16% against the industry’s negative 3% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. IART’s earnings topped estimates in each of the trailing four quarters, the average surprise being 16.8%.
Phibro Animal Health, carrying a Zacks Rank #2 at present, has an earnings yield of 9.2% compared with the industry’s 2.8% yield. Shares of the company have climbed 43.1% against the industry’s 27.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.3%.
Key Takeaways Omnicell is expanding autonomous pharmacy solutions with SaaS, services and OmniSphere adoption.OMCL is benefiting from health system wins, international expansion and recurring subscription revenue.Omnicell expects tariff costs in 2026, while labor shortages and inflation remain operational challenges. Shares of Omnicell (OMCL - Free Report) have rallied 52.6% over the past year, significantly outperforming the industry’s 20.8% fall and the S&P 500 composite’s 23.9% gain.
Sporting a Zacks Rank #1 (Strong Buy) at present, the healthcare technology company continues to pursue the vision of the autonomous pharmacy, designed to improve medication management outcomes. Growth in SaaS and Expert Services, rising adoption among health systems and international expansion further strengthen its outlook.
Headquartered in Mountain View, CA, Omnicell develops and markets end-to-end automation solutions for the medication-use process. These automation solutions contain medication and supply dispensing systems, central pharmacy storage, retrieval and packaging solutions, a bedside automation solution, a physician order management solution, a decision support application and a Web-based procurement application. The products offered by the company enable care providers to improve patient safety and increase efficiency by lowering costs.
Factors Favoring OMCL’s GrowthOmnicell continues to advance toward its goal of achieving the industry-defined vision of autonomous medication management, which is a roadmap to improving operational efficiencies and ultimately targeting zero-error medication management. Over the past several years, Omnicell has evolved from offering a single-point solution to a platform of products and services and has also secured several wins with major health systems and government health care facilities. OMCL’s ongoing R&D investments across Points of Care, Central Pharmacy and IV Compounding, Specialty Pharmacy and 340B Program and Ambulatory Care market categories are expected to deliver solutions that drive positive medication management outcomes for customers.
Image Source: Zacks Investment Research
The company derives an increasing portion of revenues from its subscription-based SaaS and Expert Services offerings, which include a combination of robotics, smart devices and intelligent software, all optimized by expert services. In recent years, Omnicell has integrated three key acquisitions, such as Specialty Pharmacy Services (formerly ReCept), FDS Amplicare and MarkeTouch Media, LL (merged into EnlivenHealth, Inc), to broaden the offerings. In 2025, SaaS and Expert Services revenues were $259 million.
In the first quarter of 2026, several health systems committed to using Omnicell's inventory optimization service, alongside central pharmacy automation and point-of-care dispensing solutions. The company announced OmniSphere in late 2024, a cloud-native platform designed to unify all Omnicell products under a single, secure infrastructure to make it simpler, safer and more connected to manage medications within a growing health system. EnlivenHealth also continues to gain traction with cross-selling and upselling communication solutions to existing customers.
Healthcare providers outside the United States are becoming increasingly aware of the benefits of automation. There is a substantial demand for adherence packaging equipment outside the domestic market. Omnicell’s international operations include its sales efforts centered in Canada, Europe, the Middle East and the Asia-Pacific regions and supply-chain efforts in Asia. Given the fact that the international market is less than 1% penetrated, with very few hospitals adopting medication control systems, this creates a solid long-term growth opportunity.
Risks for OMCLSimilar to its health-care system partners, Omnicell’s operations continue to be affected by persisting labor shortages as well as increased inflationary costs related to components’ raw materials and freight. The company’s 2026 guidance incorporates an updated estimate of approximately $12 million in tariff-related costs impacting profitability.
A Glance at OMCL’s EstimatesThe Zacks Consensus Estimate for Omnicell's earnings per share (EPS) is pegged at $1.97 for 2026 and $2.23 for 2027, implying year-over-year growth of 21.6% and 13.2%, respectively. Over the past 60 days, the consensus estimate for 2026 EPS has moved up 5.3%, while the 2027 estimate has increased 2.3%.
Revenues for 2026 are projected to grow 4.9% to $1.24 billion, and another 4.2% to $1.30 billion in 2027.
Other Key StocksSome other top-ranked stocks in the broader medical space are Illumina (ILMN - Free Report) , Align Technology (ALGN - Free Report) and Integra LifeSciences (IART - Free Report) .
Illumina has an earnings yield of 2.8% compared to the industry’s negative 14.6% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 12.2%. ILMN shares have rallied 95.8% compared with the industry’s 25.6% growth over the past year.
ILMN carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology, carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 10.3% compared with the industry’s 5.5% growth. Shares of the company have dipped 6.3% against the industry’s 9.6% growth. ALGN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 7.8%.
Integra LifeSciences, carrying a Zacks Rank #2, has an earnings yield of 13.7% against the industry’s negative 3% yield. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.7%. IART shares have rallied 33.8% against the industry’s 10.5% decline over the past year.
Njoku continues to lead global operations and advance Omnicell's innovation and AI platform strategy; Randall Lipps continues to serve as Chief Executive Officer and Chairman of the Board
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell” or the “Company”), a leading healthcare technology provider focused on empowering autonomous medication management, today announced that Nnamdi Njoku has been appointed President of the Company, effective July 1, 2026. Mr. Njoku will retain his role of Chief Operating Officer (COO), while Randall Lipps will continue to serve as Chief Executive Officer and Chairman of the Board, with a continued focus on strategic collaborations and the long-term evolution of Omnicell's solution portfolio.
As President and COO, Mr. Njoku will shape and advance Omnicell’s long-term growth strategy and innovation roadmap, focused on scaling global operations while seeking to ensure seamless operational execution and excellence across product, innovation, and customer experience. In this role, he will also continue to drive key business initiatives including the launch of the Omnicell Titan XT automated dispensing system and expansion of the cloud-native OmniSphere platform.
“Since joining Omnicell in 2024, Nnamdi has made a significant strategic impact on the Company, working to strengthen our operational foundation, shape our strategic direction and organizational design, and build strong relationships with our customers and the investment community,” said Mr. Lipps. “Nnamdi is a proven leader who brings clarity, discipline, and precision to our efforts to scale our business and accelerate momentum for our strategy. This appointment reflects a natural evolution of our leadership structure and allows me to be laser-focused on strategic customer and industry relationships, the evolution of our solution offerings, and our long-term vision.”
Prior to joining Omnicell, Mr. Njoku served more than 18 years in various executive leadership roles at Medtronic plc, including serving as Senior Vice President and President for the Neuromodulation Operating Unit, an approximately $2 billion business focused on harnessing the power of neuromodulation to treat conditions like pain and movement disorders. Throughout his career, Mr. Njoku has held operational roles of increasing responsibility, including at Zimmer Biomet Holdings, Inc., Medtronic, plc, UnitedHealth Group and Deloitte Consulting.
“As care delivery grows more distributed and complex, and financial and operational pressures intensify, we believe healthcare leaders need a trusted partner focused on delivering the innovation and intelligence that drives real outcomes,” said Mr. Njoku. “I’m excited to lead Omnicell through our next planned phase of growth as we strive to scale the business and execute on our strategy to transform our customers’ clinical and operational performance.”
Mr. Njoku holds a Master of Business Administration from Cornell University and a Bachelor of Arts degree in Business Administration from the University of St. Thomas. He is a Fellow of the fourth class of Aspen Institute’s Health Innovators Fellowship and a member of the Aspen Global Leadership Network, recognitions that focus on advancing leadership in health innovation.
About Omnicell
Since 1992, Omnicell has been committed to delivering innovative, outcomes-centric pharmacy and nursing solutions for all settings of care. As an intelligent medication management technology company, Omnicell empowers autonomous medication management by unifying automation and AI-enabled intelligence, optimized by expert services, to drive clinical and business outcomes that improve efficiency and enhance patient safety for healthcare facilities worldwide. Learn more at omnicell.com.
Forward-Looking Statements
To the extent any statements contained in this press release deal with information that is not historical, these statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, statements including the words “expect,” “intend,” “may,” “will,” “should,” “would,” “could,” “plan,” “potential,” “anticipate,” “believe,” “forecast,” “guidance,” “outlook,” “goals,” “target,” “estimate,” “seek,” “predict,” “project,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside Omnicell’s control. Such statements include, but are not limited to, Omnicell’s ability to deliver innovation and intelligence that drives real outcomes, scale our business, and execute our strategy, as well as other statements about Omnicell’s strategy, plans, objectives, promise, purpose and guiding principles, and goals. Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, (i) unfavorable general economic and market conditions, including the impact and duration of inflationary pressures, (ii) Omnicell’s ability to recruit and retain skilled and motivated personnel, (iii) risks related to Omnicell’s investments in new business strategies or initiatives, including its transition to selling more products and services on a subscription basis, and its ability to acquire companies, businesses, or technologies and successfully integrate such acquisitions, (iv) Omnicell’s ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, and (v) other risks and uncertainties further described in the “Risk Factors” section of Omnicell’s most recent Annual Report on Form 10-K, as well as in Omnicell’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov. Forward-looking statements should be considered in light of these risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Omnicell (OMCL - Free Report) Headquartered in Mountain View, CA, Omnicell Inc., develops and markets end-to-end automation solutions for the medication-use process. These automation solutions contain medication and supply dispensing systems, central pharmacy storage, retrieval and packaging solutions, a bedside automation solution, a physician order management solution, a decision support application, and a Web-based procurement application.
OMCL is a #1 (Strong Buy) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 20.74; value investors should take notice.
For fiscal 2026, one analyst revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.10 to $1.97 per share. OMCL boasts an average earnings surprise of +34.7%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, OMCL should be on investors' short list.
Investors in Omnicell, Inc. (OMCL - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Aug. 21, 2026 $65.00 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?Clearly, options traders are pricing in a big move for Omnicell shares, but what is the fundamental picture for the company? Currently, Omnicell is a Zacks Rank #1 (Strong Buy) in the Medical Info Systems industry that ranks in the Top 45% of our Zacks Industry Rank. Over the last 60 days, two analysts have increased their earnings estimates for the current quarter, while none have dropped their estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from 38 cents per share to 48 cents in that period.
Given the way analysts feel about Omnicell right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.
Below, we take a look at Omnicell (OMCL - Free Report) , which currently has a Momentum Style Score of A. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Omnicell currently has a Zacks Rank of #1 (Strong Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.
You can see the current list of Zacks #1 Rank Stocks here >>>
Set to Beat the Market? In order to see if OMCL is a promising momentum pick, let's examine some Momentum Style elements to see if this Omnicell Inc. holds up.
Looking at a stock's short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.
For OMCL, shares are up 14.53% over the past week while the Zacks Medical Info Systems industry is up 1.91% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 27.35% compares favorably with the industry's 7.94% performance as well.
While any stock can see its price increase, it takes a real winner to consistently beat the market. That is why looking at longer term price metrics -- such as performance over the past three months or year -- can be useful as well. Over the past quarter, shares of Omnicell have risen 19.01%, and are up 42.47% in the last year. In comparison, the S&P 500 has only moved 4.92% and 28.12%, respectively.
Investors should also pay attention to OMCL's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. OMCL is currently averaging 627,607 shares for the last 20 days.
Earnings OutlookThe Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with OMCL.
Over the past two months, 2 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost OMCL's consensus estimate, increasing from $1.78 to $1.98 in the past 60 days. Looking at the next fiscal year, 1 estimate has moved upwards while there have been 1 downward revision in the same time period.
Bottom LineGiven these factors, it shouldn't be surprising that OMCL is a #1 (Strong Buy) stock and boasts a Momentum Score of A. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep Omnicell on your short list.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +23.93% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Omnicell (OMCL - Free Report) Headquartered in Mountain View, CA, Omnicell Inc., develops and markets end-to-end automation solutions for the medication-use process. These automation solutions contain medication and supply dispensing systems, central pharmacy storage, retrieval and packaging solutions, a bedside automation solution, a physician order management solution, a decision support application, and a Web-based procurement application.
OMCL is a #1 (Strong Buy) on the Zacks Rank, with a VGM Score of A.
Momentum investors should take note of this Medical stock. OMCL has a Momentum Style Score of A, and shares are up 23% over the past four weeks.
Two analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.20 to $1.98 per share. OMCL also boasts an average earnings surprise of +34.7%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, OMCL should be on investors' short list.
Omnicell (OMCL - Free Report) closed the last trading session at $43.82, gaining 19.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $61.29 indicates a 39.9% upside potential.
The average comprises seven short-term price targets ranging from a low of $55.00 to a high of $70.00, with a standard deviation of $6.82. While the lowest estimate indicates an increase of 25.5% from the current price level, the most optimistic estimate points to a 59.7% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.
While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice.
However, an impressive consensus price target is not the only factor that indicates a potential upside in OMCL. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside.
Price, Consensus and EPS Surprise
Here's What You Should Know About Analysts' Price TargetsAccording to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.
While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?
They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.
However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.
That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.
Here's Why There Could be Plenty of Upside Left in OMCLAnalysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason to expect an upside in the stock. That's because empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
The Zacks Consensus Estimate for the current year has increased 43.4% over the past month, as three estimates have gone higher compared to no negative revision.
Moreover, OMCL currently has a Zacks Rank #1 (Strong Buy), which means it is in the top 5% of more than 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Therefore, while the consensus price target may not be a reliable indicator of how much OMCL could gain, the direction of price movement it implies does appear to be a good guide.
Omnicell, Inc. (OMCL - Free Report) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, OMCL's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross."
A golden cross is a technical chart pattern that can signify a potential bullish breakout. It's formed from a crossover involving a security's short-term moving average breaking above a longer-term moving average, with the most common moving averages being the 50-day and the 200-day, since bigger time periods tend to form stronger breakouts.
Golden crosses have three key stages that investors look out for. It starts with a downtrend in a stock's price that eventually bottoms out, followed by the stock's shorter moving average crossing over its longer moving average and triggering a trend reversal. The final stage is when a stock continues the upward climb to higher prices.
This kind of chart pattern is the opposite of a death cross, which is a technical event that suggests future bearish price movement.
OMCL could be on the verge of a breakout after moving 20.3% higher over the last four weeks. Plus, the company is currently a #1 (Strong Buy) on the Zacks Rank.
Once investors consider OMCL's positive earnings outlook for the current quarter, the bullish case only solidifies. No earnings estimate has gone lower in the past two months compared to 3 revisions higher, and the Zacks Consensus Estimate has increased as well.
Investors may want to watch OMCL for more gains in the near future given the company's key technical level and positive earnings estimate revisions.
Key Takeaways Omnicell shares gained 57.3% in a year, outperforming the industry's 30.4% decline.OMCL expanded Autonomous Pharmacy offerings with OmniSphere and launched Titan XT in 2025.Omnicell expects 2026 revenue growth of 4.9% and higher EPS despite tariff-related costs. Omnicell (OMCL - Free Report) has seen impressive growth over the past year, with its shares jumping 57.3%. It has significantly outperformed the industry’s 30.3% fall and the S&P 500 composite’s 33% gain.
Sporting a Zacks Rank #1 (Strong Buy) at present, the healthcare technology company is advancing the vision of Autonomous Pharmacy, supporting improved medication management outcomes. Growth in SaaS and Expert Services, along with the rising adoption of its solutions among health systems, strengthens its outlook. Solid financial health further adds to its appeal.
Headquartered in Mountain View, CA, Omnicell Inc. develops and markets end-to-end automation solutions for the medication-use process. These automation solutions contain medication and supply dispensing systems, central pharmacy storage, retrieval and packaging solutions, a bedside automation solution, a physician order management solution, a decision support application and a Web-based procurement application. The products offered by the company enable care providers to improve patient safety and increase efficiency by lowering costs.
Factors Favoring OMCL’s GrowthThe rally in the company’s share price can be linked to the continued momentum across the core businesses. Over the past several years, Omnicell has expanded its business from a single-point solution to a platform of products and services that will help further advance Autonomous Pharmacy, the industry-defined vision to improve operational efficiencies and ultimately target zero-error medication management. Its ongoing R&D investments across Points of Care, Central Pharmacy and IV Compounding, Specialty Pharmacy and 340B Program, and Ambulatory Care market categories are expected to deliver solutions that drive positive medication management outcomes for customers.
Image Source: Zacks Investment Research
To expand its market presence, the company is actively working to grow its product footprint across both inpatient and outpatient care environments, including nursing units, operating rooms and a full spectrum of pharmacy settings. Omnicell’s cloud-native platform, OmniSphere, is designed to bring all its products under a single, secure infrastructure to make it simpler, safer and more connected to manage medications within a growing health system.
In December 2025, the company introduced Titan XT, which offers enterprise-wide visibility, centralized inventory management, guided workflows and a modern infrastructure to support the shift toward autonomous medication management. The launch received a positive early response.
Omnicell derives an increasing portion of revenues from its subscription-based SaaS and Expert Services offerings, which include a combination of robotics, smart devices and intelligent software, all optimized by expert services. In recent years, the company has integrated three key acquisitions, such as Specialty Pharmacy Services (formerly ReCept), FDS Amplicare and MarkeTouch Media, LL (merged into EnlivenHealth, Inc), to broaden the offerings. In the first quarter of 2026, several health systems committed to using Omnicell's inventory optimization service, alongside central pharmacy automation and point-of-care dispensing solutions.
Meanwhile, Omnicell exited the first quarter of 2026 with cash and cash equivalents of $239.2 million and $168 million in total debt, reflecting a healthy liquidity position and balance sheet strength.
Risks for OMCLSimilar to its health-care system partners, Omnicell’s operations continue to be affected by persisting labor shortages as well as increased inflationary costs related to components’ raw materials and freight. In response to changing tariffs, several foreign countries have imposed reciprocal duties on U.S.-manufactured goods. The 2026 guidance incorporates an updated estimate of approximately $12 million in tariff-related costs impacting the P&L.
A Glance at OMCL’s EstimatesThe Zacks Consensus Estimate for Omnicell’s 2026 and 2027 earnings per share (EPS) is expected to increase 21.6% and 13.2% year over year, respectively, to $1.97 and $2.23. In the past 30 days, the Zacks Consensus Estimate for the company's 2026 EPS has risen 13.2%.
Revenues for 2026 are projected to grow 4.9% to $1.24 billion, while the same for 2027 are expected to reach $1.30 billion.
Other Key StocksSome other top-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Align Technology (ALGN - Free Report) and Integra LifeSciences (IART - Free Report) .
Globus Medical has an earnings yield of 6.1% compared to the industry’s negative 1.1% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 26.3%. GMED shares have rallied 43.8% against the industry’s 4.8% fall over the past year.
GMED sports a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology, carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 10.3% for fiscal 2026 compared with the industry’s 9.5% growth. Shares of the company have dropped 4.2% compared to the industry’s 5% rise. ALGN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 7.8%.
Integra LifeSciences, carrying a Zacks Rank #2, has an earnings yield of 15.7% against the industry’s negative 15.7% yield. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.7%. IART shares have rallied 22.8% against the industry’s 4.8% decline over the past year.
A month has gone by since the last earnings report for Omnicell (OMCL - Free Report) . Shares have added about 0.1% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Omnicell due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for Omnicell, Inc. before we dive into how investors and analysts have reacted as of late.
Omnicell Q1 Earnings & Revenues Top, Gross Margin RisesOmnicell, Inc. (OMCL - Free Report) reported first-quarter 2026 adjusted earnings per share (EPS) of 55 cents, up 111.5% year over year. The metric beat the Zacks Consensus Estimate by 67.94%.
Adjustments include one-time expenses like share-based compensations, the amortization of acquired intangibles, acquisition-related expenses, executive transition costs and others.
GAAP earnings were 25 cents per share in the quarter under review compared to a loss of 15 cents in the prior-year quarter.
OMCL’s Revenue DetailsRevenues in the first quarter totaled $310 million, up 15% year over year. This was driven by strength in the connected devices offerings, as well as increases in technical services, SaaS and Expert Services, and consumables revenues. The figure beat the Zacks Consensus Estimate by 2.2%.
On a segmental basis, Product revenues rose 20.4% year over year to $174.8 million in the reported quarter. Service revenues climbed 8.5% year over year to $135.1 million.
OMCL’s Operational UpdateIn the quarter under review, the gross profit rose 26.5% to $140.4 million. The gross margin expanded 416 basis points (bps) to 45.3% despite a 6.8% rise in the cost of revenues.
Operating expenses amounted to $123.5 million, up 0.8% year over year. The operating profit in the quarter totaled $16.8 million compared to an operating loss of $11.6 million in the year-ago quarter.
OMCL’s Financial UpdateOmnicell exited the first quarter of 2026 with cash and cash equivalents of $239.2 million compared with $196.5 million at the end of 2025.
The cumulative cash flow provided by operating activities at the end of the first quarter was $54.5 million compared with $25.9 million a year ago.
Omnicell’s 2026 OutlookFor full-year 2026, the company continues to expect revenues in the range of $1.215-$1.255 billion. Within this, Product revenues are expected to be in the band of $690-$710 million and Service revenues in the range of $525-$545 million. The Zacks Consensus Estimate for total revenues is pegged at $1.24 billion.
Adjusted EPS for the full year is expected between $1.80 and $2.00, up from the previous guidance of $1.65-$1.85. The Zacks Consensus Estimate is pegged at $1.77.
For the second quarter of 2026, Omnicell expects $307-$313 million in total revenues, comprising Product revenues of $174-$177 million and Service revenues of $133-$136 million. The Zacks Consensus Estimate for second-quarter revenues is pinned at $309.6 million.
Adjusted EPS for the second quarter is expected between 40 cents and 48 cents. The Zacks Consensus Estimate is pegged at 41 cents.
How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a upward trend in fresh estimates.
The consensus estimate has shifted 60.53% due to these changes.
VGM ScoresCurrently, Omnicell has a nice Growth Score of B, though it is lagging a bit on the Momentum Score front with a C. Following the exact same course, the stock was allocated a score of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Omnicell has a Zacks Rank #1 (Strong Buy). We expect an above average return from the stock in the next few months.
Shares of Omnicell (OMCL - Free Report) have been struggling lately and have lost 6.3% over the past two weeks. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.
While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future earnings of this Omnicell Inc. is a solid fundamental factor that enhances the prospects of a trend reversal for the stock.
Understanding Hammer Chart and the Technique to Trade ItThis is one of the popular price patterns in candlestick charting. A minor difference between the opening and closing prices forms a small candle body, and a higher difference between the low of the day and the open or close forms a long lower wick (or vertical line). The length of the lower wick being at least twice the length of the real body, the candle resembles a 'hammer.'
In simple terms, during a downtrend, with bears having absolute control, a stock usually opens lower compared to the previous day's close, and again closes lower. On the day the hammer pattern is formed, maintaining the downtrend, the stock makes a new low. However, after eventually finding support at the low of the day, some amount of buying interest emerges, pushing the stock up to close the session near or slightly above its opening price.
When it occurs at the bottom of a downtrend, this pattern signals that the bears might have lost control over the price. And, the success of bulls in stopping the price from falling further indicates a potential trend reversal.
Hammer candles can occur on any timeframe -- such as one-minute, daily, weekly -- and are utilized by both short-term as well as long-term investors.
Like every technical indicator, the hammer chart pattern has its limitations. Particularly, as the strength of a hammer depends on its placement on the chart, it should always be used in conjunction with other bullish indicators.
Here's What Makes the Trend Reversal More Likely for OMCLAn upward trend in earnings estimate revisions that OMCL has been witnessing lately can certainly be considered a bullish indicator on the fundamental side. That's because empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
Over the last 30 days, the consensus EPS estimate for the current year has increased 18.1%. What it means is that the sell-side analysts covering OMCL are majorly in agreement that the company will report better earnings than they predicted earlier.
If this is not enough, you should note that OMCL currently has a Zacks Rank #1 (Strong Buy), which means it is in the top 5% of more than 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. And stocks carrying a Zacks Rank #1 or 2 usually outperform the market. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Moreover, a Zacks Rank of 1 for Omnicell is a more conclusive indication of a potential trend reversal, as the Zacks Rank has proven to be an excellent timing indicator that helps investors identify precisely when a company's prospects are beginning to improve.
Key Takeaways Omnicell is advancing its Autonomous Pharmacy vision with R&D and major health system wins.Omnicell is growing SaaS and Expert Services, supported by OmniSphere and new automation offerings.OMCL's 2026 EPS estimate rose 5.3% in 30 days, while revenues are projected to grow 4.9%. Omnicell (OMCL - Free Report) is well-poised to grow in the coming quarters as it continues to steadily advance the autonomous pharmacy industry-defined vision for delivering improved medication management outcomes. Growth in SaaS and Expert Services, rising adoption among health systems and international expansion strengthen its outlook. However, macroeconomic headwinds and competitive pressures could weigh on its operating performance.
Over the past year, this Zacks Rank #1 (Strong Buy) stock has had a remarkable run. OMCL shares have risen 35.7% compared to the 31.6% fall of the industry and the 31.7% growth of the S&P 500 composite.
The renowned healthcare technology company has a market capitalization of $1.91 billion. OMCL’s earnings yield of 4.7% is comfortably above the industry’s negative 1% yield. In the trailing four quarters, Omnicell surpassed earnings estimates thrice and missed on one occasion, the average surprise being 34.7%.
Let’s delve deeper.
Tailwinds for OMCL StockAutonomous Pharmacy Model Holds Potential: The industry-defined vision of Autonomous pharmacy is a roadmap to improving operational efficiencies and ultimately targeting zero-error medication management. Over the past several years, Omnicell has expanded its business from a single-point solution to a platform of products and services that will help further advance the vision.
The company also secured several wins with major health systems and government health care facilities. Omnicell’s ongoing R&D investments across Points of Care, Central Pharmacy and IV Compounding, Specialty Pharmacy, 340B Program and Ambulatory Care market categories are expected to deliver solutions that drive positive medication management outcomes for customers.
Image Source: Zacks Investment Research
Robust Pipeline for SaaS and Expert Services Portfolio: Omnicell derives an increasing portion of revenues from its subscription-based SaaS and Expert Services offerings, which include a combination of robotics, smart devices and intelligent software, all optimized by expert services. In recent years, the company has integrated three key acquisitions, such as Specialty Pharmacy Services (formerly ReCept), FDS Amplicare and MarkeTouch Media, LL (merged into EnlivenHealth, Inc), to broaden the offerings.
The company announced OmniSphere in late 2024, designed to be the connected backbone for all Omnicell products. The same year, it introduced Central Med Automation Service, a subscription-based solution designed to help health systems establish and continuously optimize centralized medication management for consolidated pharmacy service centers (CPSCs) and similar operations. In the first quarter of 2026, several health systems committed to using Omnicell's inventory optimization service, alongside central pharmacy automation and point-of-care dispensing solutions.
Planned Geographic Expansion Another Upside: Outside the United States, healthcare providers are becoming increasingly aware of the benefits of automation. There is a substantial demand for adherence packaging equipment outside the domestic market. Many government and private entities are aware of the progress made over the last several years in the United States and are investing significantly in information technology and automation.
The company’s international operations include its sales efforts centered in Canada, Europe, the Middle East, and the Asia-Pacific regions and supply chain efforts in Asia. Given the fact that the international market is less than 1% penetrated, with very few hospitals adopting medication control systems, Omnicell intends to expand into new markets, which it views as strategic.
What Ails Omnicell?Escalating Expenses May Strain Margins: Similar to its health-care system partners, the company’s operations continue to be affected by persisting labor shortages as well as increased inflationary costs related to components’ raw materials and freight. Changes in export or import regulations and other trade barriers may have an adverse effect on the company’s business.
Competitive Landscape: Omnicell faces intense competition in the medication management and supply-chain solutions market. Even though the company continues to gain market share from other traditional providers of medication management and supply-chain solutions, major players still pose threats as they spearhead several expansion programs. This increased competition could result in pricing pressure and a reduced margin.
OMCL Stock Estimate TrendThe Zacks Consensus Estimate for OMCL’s 2026 earnings per share (EPS) has jumped 5.3% to $1.97 in the past 30 days.
The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $1.24 billion. This suggests a 4.9% increase from the year-ago reported number.
Other Key PicksSome other top-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Align Technology (ALGN - Free Report) and Integra LifeSciences (IART - Free Report) .
Globus Medical has an earnings yield of 6.1% compared to the industry’s negative 1.9% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 26.3%. GMED shares have rallied 30.8% against the industry’s 6.4% fall over the past year.
GMED sports a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology, sporting a Zacks Rank #1, has an estimated long-term earnings growth rate of 10.3% compared with the industry’s 9.5% growth. Shares of the company have dropped 10.3% against the industry’s 2.3% rise. ALGN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 7.8%.
Integra LifeSciences, carrying a Zacks Rank #2, has an earnings yield of 15.4% against the industry’s negative 1.9% yield. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.7%. IART shares have rallied 21.2% against the industry’s 6.4% decline over the past year.
On June 04, 2026, Omnicell Inc OMCL shares rose 4.1% to a current price of $43.62. This performance comes amid a volatile trading period, with the stock's 52-week range between $26.85 and $55.00. The recent movement in stock price has drawn attention as it fluctuates in the context of its historical performance.
GF Value™ verdict: The current price is $43.62, which is 12.9% above the GF Value™ of $38.65.GF Score™: 78/100, indicating an above-average potential for long-term returns.Most notable signal: Insider activity shows that insiders sold $0.6 million in shares over the last three months, with no buying activity reported. Is OMCL Overvalued or Undervalued? According to the GF Value™, Omnicell Inc is currently overvalued with a market price of $43.62 compared to its intrinsic value estimate of $38.65. This presents a margin of safety of approximately 12.9% for those considering an investment based on the current valuation metrics. The GF Valuation label categorizes the stock as modestly overvalued, suggesting potential risks for investors who may be looking for a favorable entry point.
Being overvalued implies that there may be limited upside and increased risk of price corrections in the future. Investors should approach with caution, as an overvaluation can lead to volatility. The GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.
How Does OMCL's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 99.1x 91.4x Forward P/E 22.5x N/A Omnicell's current P/E ratio of 99.1x is above its 5-year median of 91.4x, indicating that the stock is trading at a premium compared to its historical valuation. The forward P/E of 22.5x suggests expectations for improved earnings in the future, but the current P/E analysis aligns with the GF Value™ verdict, reinforcing the notion that the stock is overvalued at this time.
What Does OMCL's GF Score™ Tell Us? Metric Rating GF Score™ 78 Financial Strength 6/10 Profitability 6/10 Growth 5/10 Valuation 7/10 Momentum 10/10 The GF Score™ of 78/100 indicates that Omnicell Inc has above-average potential for long-term returns. The strongest area is its Momentum rank of 10/10, suggesting strong recent performance. However, the Growth rank of 5/10 indicates that growth prospects may not be as robust, which could be a concern for future valuation.
What Are Insiders Doing with OMCL Stock? In the past three months, insiders have sold $0.6 million worth of Omnicell stock without any reported buying activity. This pattern of insider selling may suggest a lack of confidence among company executives regarding the stock's future performance. Typically, insider buying is viewed positively, while selling can be interpreted as a signal that insiders believe the stock is currently overvalued or that they anticipate challenges ahead.
What This Means for Investors Based on the GF Value™ assessment, Omnicell Inc is currently overvalued. Investors may want to exercise caution and consider waiting for a more favorable valuation before making investment decisions.
For the complete analysis, visit the Omnicell Inc OMCL stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is OMCL's GF Score™?
The GF Score™ for Omnicell Inc is 78/100, indicating an above-average potential for long-term returns based on various key metrics.
Is OMCL overvalued or undervalued?
According to the GF Value™ assessment, Omnicell Inc is currently overvalued, with the market price exceeding its intrinsic value estimate by 12.9%.
What is OMCL's P/E ratio?
Omnicell Inc has a trailing P/E ratio of 99.1x, which is above its 5-year median P/E of 91.4x, indicating that it is trading at a premium compared to its historical valuation.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Omnicell (OMCL - Free Report) Headquartered in Mountain View, CA, Omnicell Inc., develops and markets end-to-end automation solutions for the medication-use process. These automation solutions contain medication and supply dispensing systems, central pharmacy storage, retrieval and packaging solutions, a bedside automation solution, a physician order management solution, a decision support application, and a Web-based procurement application.
OMCL is a #1 (Strong Buy) on the Zacks Rank, with a VGM Score of B.
Momentum investors should take note of this Medical stock. OMCL has a Momentum Style Score of B, and shares are up 0.6% over the past four weeks.
Three analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.23 to $1.97 per share. OMCL boasts an average earnings surprise of +34.7%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, OMCL should be on investors' short list.
Shares of Omnicell (OMCL - Free Report) have gained 0.6% over the past four weeks to close the last trading session at $43.6, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $61.29 indicates a potential upside of 40.6%.
The mean estimate comprises seven short-term price targets with a standard deviation of $6.82. While the lowest estimate of $55.00 indicates a 26.2% increase from the current price level, the most optimistic analyst expects the stock to surge 60.6% to reach $70.00. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.
While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice.
But, for OMCL, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside.
Price, Consensus and EPS Surprise
Here's What You May Not Know About Analysts' Price TargetsAccording to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.
While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?
They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.
However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.
That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.
Here's Why There Could be Plenty of Upside Left in OMCLAnalysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason to expect an upside in the stock. That's because empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
The Zacks Consensus Estimate for the current year has increased 18.1% over the past month, as one estimate has gone higher compared to no negative revision.
Moreover, OMCL currently has a Zacks Rank #1 (Strong Buy), which means it is in the top 5% of more than 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Therefore, while the consensus price target may not be a reliable indicator of how much OMCL could gain, the direction of price movement it implies does appear to be a good guide.
An updated edition of the April 16, 2026, article.
The American robotics industry has entered a decisive acceleration phase in 2026, with recent months emerging as a landmark across physical AI, surgical systems, defense autonomy, collaborative robotics and elder care — reinforcing a strong investment case for sector leaders, including ABB (ABBNY - Free Report) , Microchip Technology (MCHP - Free Report) , Omnicell (OMCL - Free Report) and Teradyne (TER - Free Report) .
Physical AI Enters the Production EraPhysical AI is now a multi-player race. During National Robotics Week, NVIDIA (NVDA - Free Report) made the open-source Newton Physics Engine 1.0 generally available — co-developed with Google DeepMind and Disney Research — providing a GPU-accelerated simulation foundation for dexterous robot manipulation with accurate collision detection and realistic contact modeling. NVIDIA then unveiled the Isaac GR00T Reference Humanoid Robot at GTC Taipei in late May, pairing a Unitree H2 Plus chassis with Sharpa five-fingered hands and Jetson Thor onboard compute, with commercial availability from Unitree targeted for late 2026.
Google DeepMind has been equally active, as it introduced Gemini Robotics-ER 1.6, upgrading its embodied reasoning model with enhanced spatial reasoning, multi-view success detection and new instrument-reading capabilities developed in collaboration with Boston Dynamics, enabling robots to autonomously read industrial gauges and operate in factories and warehouses. On the venture front, Mind Robotics — a Rivian spinout building AI-powered factory robots — became a unicorn after raising a $500 million Series A in March, and followed up with a further $400 million raise in May to accelerate industrial deployments with partner Rivian.
Manufacturing and Collaborative Robotics AccelerateIn a pivotal consolidation, Skild AI — valued at more than $14 billion — acquired Zebra Technologies' robotics automation division on April 15, bringing the Symmetry Fulfillment orchestration platform under its omni-bodied AI layer. The combined entity now aims to provide a full end-to-end warehouse solution, spanning humanoids for pick-place, robotic arms for packing, AMRs for material movement, and a single orchestration layer to control all form factors.
Meanwhile, OpenAI-backed 1X Technologies launched full-scale production at its 58,000-square-foot NEO humanoid factory in Hayward, CA — the most vertically integrated humanoid robot facility in the United States — targeting 10,000 units in its first year, with consumer shipments planned for 2026 and output scaling to 100,000 units by the end of 2027.
Surgical and Medical Robotics Widen Their ReachIntuitive Surgical reported a 23% revenue increase to $2.77 billion in first-quarter 2026, with da Vinci procedures growing 16% and 431 system placements, including 232 da Vinci 5 units, prompting a guidance raise to 13.5-15.5% full-year procedure growth. CMR Surgical filed a further FDA 510(k) submission in April to expand Versius Plus into benign gynecologic procedures, intensifying competition for Intuitive's dominant market share. The global surgical robotics market is valued at $14.45 billion in 2026, with North America holding a 51% share.
Defense, Space and Elder Care Gain MomentumThe global defense robotics market was valued at $21.2 billion in 2025, with more than 61% of U.S. military modernization projects now incorporating robotic technologies. In elder care, University of New Hampshire researchers, piloting a care robot named Stretch 4 with National Institute on Aging funding, showcased in April how autonomous assistive robots are beginning to address the worsening U.S. caregiver shortage in real home settings. Industry forecasters see consumer and developer humanoid deployments scaling from 2027, with medical and elder care applications forming the largest long-term wave from 2030 onward.
Outlook and Investment OpportunityWith physical AI infrastructure now spanning NVIDIA, Google DeepMind and a new wave of well-funded independents, the first meaningful home deployments and broad warehouse standardization are expected between 2027 and 2028, when the humanoid market is forecast to cross $10 billion — a trajectory supported by falling hardware costs, Robot-as-a-Service models and deepening defense procurement. Across manufacturing, surgical suites, battlefields and care homes, 2026 is laying the foundation for a decisive multi-year expansion.
The Robotics Screen makes it easy to identify high-potential stocks at any given time, just like the ones discussed below. Leveraging advanced tools, the thematic screens identify companies shaping the future, making it easier to capitalize on emerging trends.
Ready to uncover more transformative thematic investment ideas? Explore 30 cutting-edge investment themes with Zacks Thematic Screens and discover your next big opportunity.
ABB presents a compelling robotics investment opportunity anchored by a series of meaningful product advances. In April 2026, ABB Robotics launched the high-speed PoWa cobot family, delivering industry-leading speeds of 5.8 m/s, payloads up to 30kg, and the longest reach in its class, meaningfully lowering the automation barrier for SMEs and large enterprises alike. This Zacks Rank #1 (Strong Buy) company partnered with Jacobi Robotics to bring productized mixed-case palletizing solutions to system integrators. Looking ahead, the imminent divestiture of the Robotics division to SoftBank Group positions ABB Robotics to leverage SoftBank's formidable AI and next-generation computing ecosystem — a powerful catalyst that could supercharge its autonomous, versatile robotics ambitions across industries worldwide. You can see the complete list of today’s Zacks #1 Rank stocks here.
Microchip Technology is emerging as a standout investment in robotics. In April 2026, it earned IEC 62443-4-1 ML2 Industrial Automation and Control System certification, establishing its embedded development processes meet globally recognized secure-by-design standards — a critical differentiator for trusted robotic deployments. This Zacks Rank #1 company also expanded its dsPIC33A Digital Signal Controller family with advanced motor control capabilities, directly powering the joint-level precision that modern robots demand. Last month, next-generation Single Pair Ethernet PHYs integrating Time-Sensitive Networking and functional safety bolstered its industrial connectivity portfolio for robotic systems. With smaller-form-factor PCIe switches expanding its Physical AI and humanoid robotics footprint, MCHP is positioned as a compelling, purpose-built robotics enabler.
Omnicell’s management highlighted Titan XT — its next-generation automated dispensing system — securing initial customer orders, with hardware shipments set to begin in the second half of 2026. The company is actively integrating new robotics innovations and advanced world models with its OmniSphere cloud-native platform, accelerating meaningful progress toward a fully autonomous pharmacy. Expanded deployments with the U.S. Department of Veterans Affairs underscore growing institutional confidence in Omnicell's robotic solutions. With a robust Titan XT demo pipeline and a $2.5 billion-plus replacement cycle opportunity ahead, this Zacks Rank #1 company's robotics strategy positions it strongly for sustained, long-term growth in healthcare automation.
Teradyne's Robotics revenues reached $91 million in first-quarter 2026 — the segment's fourth consecutive quarter of sequential growth, with strong customer engagement across e-commerce, electronics manufacturing and semiconductor end markets. Teradyne Robotics and Flex expanded their collaboration, with Flex both deploying Universal Robots cobots and MiR autonomous mobile robots in its own facilities and manufacturing key robotics components for Teradyne's customers worldwide. Separately, a German court issued a preliminary injunction barring Elite Robots Germany from distributing software alleged to infringe Universal Robots' intellectual property — a decisive win that reinforces the competitive moat around UR's proprietary platform. With a U.S. manufacturing hub set to open in late 2026, this Zacks Rank #1 company's robotics division is well-positioned to capitalize on industrial reshoring and AI-driven automation demand.
Omnicell is rated Buy, with Q1 results showing structural margin improvement and a 660 bps operating margin jump. Q1 revenue grew 15% Y/Y to $310M, with non-GAAP EPS of $0.55 beating guidance by 53% and free cash flow tripling to $39M. Management raised FY 2026 EBITDA guidance, expects margin expansion to outpace revenue growth, and continues share repurchases.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
#1 (Strong Buy) stocks have produced an unmatched +23.7% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Omnicell (OMCL - Free Report) Headquartered in Mountain View, CA, Omnicell Inc., develops and markets end-to-end automation solutions for the medication-use process. These automation solutions contain medication and supply dispensing systems, central pharmacy storage, retrieval and packaging solutions, a bedside automation solution, a physician order management solution, a decision support application, and a Web-based procurement application.
OMCL is a #1 (Strong Buy) on the Zacks Rank, with a VGM Score of A.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 20.62; value investors should take notice.
Three analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.23 to $1.97 per share. OMCL boasts an average earnings surprise of +34.7%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, OMCL should be on investors' short list.
